II-01 Åsa Kragh Population pharmacokinetic analysis of PT010, an inhaled triple fixed-dose combination product, in patients with chronic obstructive pulmonary disease Wednesday 15:10-16:40 |
II-02 Markus Krauß Mice with human livers improve First-in-Human prediction of pharmacokinetics Wednesday 15:10-16:40 |
II-03 Rukmini Kumar Quantitative Systems Pharmacology (QSP) tools to aid in model development and communication: Vantage QSP Modeling Tools (VQM-Tools) Wednesday 15:10-16:40 |
II-04 Hanna Kunina Diabetes progression modelling of competing risks of long-term complications and mortality using Swedish registry data Wednesday 15:10-16:40 |
II-05 Sofiene Laarif Quantitative modeling of inter-lesion and inter-organ variability of tumor size Wednesday 15:10-16:40 |
II-06 Jennifer Lang Combining physiologically-based-pharmacokinetic modelling and a Bayesian method for prediction of ivabradine oral absorption and drug-drug interactions Wednesday 15:10-16:40 |
II-07 Silvia Maria Lavezzi Pharmacokinetic Models for Drug and Metabolites Including First Pass Effects: A Priori and A Posteriori Identifiability Analysis Wednesday 15:10-16:40 |
II-08 Jean Lavigne Population Pharmacokinetics of Piperacillin-Tazobactam Extended Infusions in Paediatric Population Wednesday 15:10-16:40 |
II-09 Jacob Leander Development of a population pharmacokinetic model of verinurad used for simulations of various dosing scenarios in different populations Wednesday 15:10-16:40 |
II-10 Donghwan Lee Effect of Pharmacokinetic Model Misspecification on Antibiotic Probability of Target Attainment Predicted by Monte Carlo Simulation Wednesday 15:10-16:40 |
II-11 Woo Yul Lee Population pharmacokinetics of recombinant coagulation factor VIII in Korean hemophila A patients Wednesday 15:10-16:40 |
II-12 Soyoung Lee Population Pharmacokinetic Analysis for Novel Acid Pump Antagonist DWP14012 Wednesday 15:10-16:40 |
II-13 Hyun A Lee A mechanism-based pharmacokinetic/pharmacodynamic model to evaluate the mutual relationships between YH4808, a novel K+-competitive acid blocker, and intragastric pH in humans Wednesday 15:10-16:40 |
II-14 So Jin Lee The new era of pharmacokinetic/pharmacodynamic modeling and simulation in drug development in Korea Wednesday 15:10-16:40 |
II-15 Anja Lehmann Toxicokinetic modelling of hepatotoxic pyrrolizidine alkaloids: a combined in silico, in vitro and in vivo approach Wednesday 15:10-16:40 |
II-16 Rory Leisegang Establishing evidence for improved outcomes for HIV+ patients receiving antiretroviral drugs through home delivery Wednesday 15:10-16:40 |
II-17 Giulia Lestini Handling dropouts in longitudinal observational studies – an illustration of a workflow from data preparation to model building and model diagnostics in Alzheimer’s disease Wednesday 15:10-16:40 |
II-18 Yisheng Li A semi-mechanistic dose-finding design in oncology using pharmacokinetic/pharmacodynamic modeling Wednesday 15:10-16:40 |
II-19 Patrick Lilienthal Mathematical modeling of RBC count dynamics after blood loss Wednesday 15:10-16:40 |
II-20 Dan Liu Investigating Impacts of Model Parameters Correlations in Global Sensitivity Analysis: Determining the most influential parameters of a Minimal PBPK Model of Midazolam Wednesday 15:10-16:40 |
II-21 Feiyan Liu Modeling inflammatory biomarker dynamics during clinical challenge studies with lipopolysaccharide Wednesday 15:10-16:40 |
II-22 Carolina Llanos-Paez Implementation of event time distribution as a random effect in time-to-event analysis Wednesday 15:10-16:40 |
II-23 Rasmus Jansson Löfmark Translational pharmacokinetic-pharmacodynamic modelling predicts human exposure target engagement Wednesday 15:10-16:40 |
II-24 Aurelie Lombard Tumour size measurements: impact of inter-operator variability on model-based drug effect evaluation Wednesday 15:10-16:40 |
II-25 Dominik Lott Prediction of exposure and effect on total lymphocyte count following long-term treatment of healthy subjects and lupus patients with the selective S1P1 receptor modulator cenerimod Wednesday 15:10-16:40 |
II-26 Qiang Lu Population Pharmacokinetic Meta-Analysis of Dupilumab in Adult Atopic Dermatitis Patients, Asthma Patients, and Healthy Subjects Wednesday 15:10-16:40 |
II-27 Inga Ludwig A Quantitative Approach to Assess Similarity of Adult and Pediatric Efficacy to Support Full or Partial Extrapolation in Pediatric Drug Development Wednesday 15:10-16:40 |
II-28 Ulrich Ruben Luecht Physiologically based pharmacokinetic modeling approach to assess drug-drug interactions (DDI) between psychopharmaceuticals – focus on mirtazapine and venlafaxine Wednesday 15:10-16:40 |
II-29 Nicolas Luyckx Improving the performances of clinical trial simulations in Simulo using compiled code Wednesday 15:10-16:40 |
II-30 Yassine Kamal Lyauk Dose Finding in Clinical Development of 60 FDA-Approved Drugs Compared to the Learning versus Confirming Paradigm Wednesday 15:10-16:40 |
II-31 Sreenath M Krishnan A combined population kinetic-pharmacodynamic-overall survival model for docetaxel and paclitaxel in the treatment of HER2–negative metastatic breast cancer patients Wednesday 15:10-16:40 |
II-32 Guangda Ma Evaluating the influence of genotype on warfarin dose predictions made using a theory-based PKPD model. Wednesday 15:10-16:40 |
II-33 Panos Macheras On the unphysical hypotheses in pharmacokinetics and oral drug absorption:Time to utilize instantaneous rate coefficients instead of rate constants Wednesday 15:10-16:40 |
II-34 Paolo Magni Artificial intelligence and machine learning: just a hype or a new opportunity for pharmacometrics? Wednesday 15:10-16:40 |
II-35 Mats Magnusson Population PK and PASI exposure-response modelling for Certolizumab pegol in patients with chronic plaque psoriasis Wednesday 15:10-16:40 |
II-36 Corinna Maier Quantifying the uncertainty: informative decision-support in individualised chemotherapy Wednesday 15:10-16:40 |
II-37 Victor Mangas-Sanjuan Population Pharmacokinetic and exposure-efficacy Markov modelling of enzymatic activity in Gaucher disease patients treated with enzyme replacement therapy Wednesday 15:10-16:40 |
II-38 Nicolás Marco Ariño Pharmacodynamic modelling of pupil diameter after noxious stimulus in patients undergoing surgery Wednesday 15:10-16:40 |
II-39 Fatima Zahra Marok Physiologically-based pharmacokinetic modeling of DPYD substrate 5-fluorouracil and its prodrug capecitabine Wednesday 15:10-16:40 |
II-40 Frederico Martins Application of Physiologically Based Pharmacokinetic (PBPK) Modelling to Support First in Human dose selection. Wednesday 15:10-16:40 |
II-41 Paolo Mazzei Prospective Evaluation of a Model-Based approach to select Phase 1 Dosing Regimen for MEN1309/OBT076, a novel antibody drug conjugate (ADC) targeting Ly75 antigen for the treatment of CD205-positive metastatic solid tumours and Non-Hodgkin lymphoma Wednesday 15:10-16:40 |
II-42 Mark Meerson Quantitative systems pharmacology model of key intraneuronal pathways regulating toxic protein accumulation in Alzheimer’s disease Wednesday 15:10-16:40 |
II-43 Christophe Meille Combining BLRM and safety PKPD models to improve decision making in a phase I dose escalation study: case study of PCA062, an antibody drug conjugate targeting P-Cadherin Wednesday 15:10-16:40 |
II-44 Nicola Melillo Global sensitivity analysis of a physiologically based pulmonary absorption model Wednesday 15:10-16:40 |
II-45 France Mentré New version of PFIM for optimal design in nonlinear mixed effects models using R S4 Wednesday 15:10-16:40 |
II-46 Matilde Merino-Sanjuán Impact of ABC gene single nucleotide polymorphisms in population pharmacokinetic of capecitabine and its metabolites 5'-deoxy-5-fluorouridine (5'-DFUR) 5-fluorouracil (5-FU) in patients with colorectal cancer Wednesday 15:10-16:40 |
II-47 Danica Michalickova Pharmacokinetics of phenobarbital in neonates on extracorporeal membrane oxygenation Wednesday 15:10-16:40 |
II-48 Robin Michelet A workflow for application of the general pharmacodynamic interaction model on high-throughput combinatorial data in order to identify, quantify and characterise drug combinations that can overcome multi-drug-resistance Wednesday 15:10-16:40 |
II-49 Iris Minichmayr Impact of genetic variants of UGT1A1 on myelosuppression during irinotecan therapy Wednesday 15:10-16:40 |
II-50 Jonathan Mochel A Physiologically-Based Pharmacokinetic (PBPK) Model for the Prediction of Levodopa (L-dopa) Disposition in Plasma and Various Brain Compartments Across Species Wednesday 15:10-16:40 |
II-51 Daniel Moj Biotest’s Pentaglobin® in adults and neonates (term and preterm) – A PBPK approach Wednesday 15:10-16:40 |
II-52 Camille Riff Population Pharmacokinetics of Rituximab in patients with Chronic Lymphocytic Leukemia Wednesday 15:10-16:40 |
II-53 Anna Mc Laughlin Model-informed precision dosing for tamoxifen therapy in breast cancer patients: Comparison of different target attainment metrics Wednesday 15:10-16:40 |
II-54 Flora Musuamba Tshinanu Dose optimization based on control and system theory: Case of Meropenem Wednesday 15:10-16:40 |
II-55 Tadakatsu Nakamura A Model-Based Meta-Analysis (MBMA) of Efficacy of Different Drugs for Postmenopausal Vasomotor-Symptoms Wednesday 15:10-16:40 |
II-56 Ricardo Nalda-Molina Evaluation of the predictive performance and the model adequacy of four population pharmacokinetic models of adalimumab in patients with inflammatory bowel disease. Wednesday 15:10-16:40 |
II-57 Srividya Neelakantan Population Pharmacokinetic/Pharmacodynamic Modeling of PF-06480605, an Anti-TL1A Antibody, in Healthy Subjects and Ulcerative Colitis Patients Wednesday 15:10-16:40 |
II-58 Ida Neldemo The tumor time-course predicts the overall survival in non-small cell lung cancer patients treated with atezolizumab in a large Phase I study: an evaluation of using different censoring times Wednesday 15:10-16:40 |
II-59 Bernard Ngara A Semi-mechanistic population pharmacokinetic model quantifying hair concentrations of ritonavir-boosted atazanavir. A study of HIV infected Zimbabweans adolescents. Wednesday 15:10-16:40 |
II-60 Laurent Nguyen Pharmacokinetic time-dependency and covariates modelling of Isatuximab monoclonal antibody in multiple myeloma patients: analysis from pooled phase I/II & phase III studies Wednesday 15:10-16:40 |
II-61 Laura Zwep Hierarchical group LASSO with random effects: identification of high-dimensional omics-drug interactions predictive of treatment response in patient-derived tumor growth data Wednesday 15:10-16:40 |
II-62 Joakim Nyberg Implicit and efficient handling of missing covariate information using full random effects modelling Wednesday 15:10-16:40 |
II-63 Boram Ohk Population pharmacokinetic analysis of tacrolimus: The role of integrative pharmacogenetics and pharmacometabolomics Wednesday 15:10-16:40 |
II-64 Andrés Olivares-Morales Bayesian pharmacokinetic (PK) and pharmacodynamic (PD) modelling of the qEEG response to a selective GABAA a5 receptor modulator in rats to inform its use as a translational biomarker Wednesday 15:10-16:40 |
II-65 Sean Oosterholt Model-based optimisation of N-acetylcysteine for the treatment of paracetamol overdose Wednesday 15:10-16:40 |
II-66 Fernando Ortega Developing a head and neck cancer model to assess the effect of radiotherapy on tumour growth inhibition and regrowth Wednesday 15:10-16:40 |
II-67 Taniya Paiboonvong Development of physiologically based pharmacokinetic model of sitafloxacin in plasma and epithelial lining fluid Wednesday 15:10-16:40 |
II-68 Semra Palic Neopterin dynamics in pediatric patients after miltefosine treatment of visceral leishmaniasis Wednesday 15:10-16:40 |
II-69 Robert Palmér A novel joint modelling approach to estimating treatment effects on COPD exacerbations in the presence of differential discontinuations Wednesday 15:10-16:40 |
II-70 Hyeonsoo Park A population pharmacokinetic model of Glimepiride(Amaryl®) Wednesday 15:10-16:40 |
II-71 Christophe Passot A kinetic-pharmacodynamic model of palbociclib reveals an influence of body weight on neutropenia onset. Wednesday 15:10-16:40 |
II-72 Nathalie Perdaems Translational PK-RO modelling for a mAb to predict the outcome of the first in human study Wednesday 15:10-16:40 |
II-73 Carlos Perez-Ruixo Exposure-response relationships of the efficacy and safety of apalutamide (APA) in men with non-metastatic castration-resistant prostate cancer (nmCRPC) Wednesday 15:10-16:40 |
II-74 Soumya Perinparajah Pharmacodynamics of rituximab on B cells in paediatric post-HSCT patients with EBV Wednesday 15:10-16:40 |
II-75 Thomas Peyret Development of a Quantitative Systems Pharmacology Model to Support Dosing of rhPTH(1-84), a Recombinant Human Parathyroid Hormone, in Adult Patients with Hypoparathyroidism Wednesday 15:10-16:40 |
II-76 Chiara Piana Development of a translational pharmacokinetic-biomarker-efficacy model in mouse to support dose recommendation in human Wednesday 15:10-16:40 |
II-77 Philippe Pierrillas PK-PD modelling of C4 concentrations after administration of a FXR agonist in healthy volunteers and Hepatitis B patients Wednesday 15:10-16:40 |
II-78 Nikhil Pillai Single objective genetic algorithm based approach for optimal population pharmacokinetic/pharmacodynamics (PK/PD) model selection for tumor growth response Wednesday 15:10-16:40 |
II-79 Vikram Prabhakar QSP Model of Rheumatoid Arthritis, capturing range of clinical responses to Methotrexate and anti-TNF-a therapies Wednesday 15:10-16:40 |
II-80 Sudeep Pradhan Evaluation of study designs to test the intact nephron hypothesis Wednesday 15:10-16:40 |
II-81 Mélanie Prague In Silico Clinical Trials for Evaluation of HIV Short-Cycle strategies Wednesday 15:10-16:40 |
II-82 Luna Prieto Garcia Physiologically-based pharmacokinetic model for itraconazole and its metabolites: the importance of parameter sensitivity analysis Wednesday 15:10-16:40 |
II-83 Alicja Puszkiel Population pharmacokinetic analysis of tamoxifen and its six metabolites in breast cancer patients: Quantification of the impact of genetic polymorphisms and co-medications on tamoxifen metabolism Wednesday 15:10-16:40 |
II-84 Rajith Rajoli PBPK Modelling of Atovaquone Long-acting Injectable Formulations Wednesday 15:10-16:40 |
II-85 Chetan Rathi Model-Informed selection of doses and sample size for a Phase 2a POC study of GSK3640254, a next generation HIV-1 maturation inhibitor Wednesday 15:10-16:40 |
II-86 Michael Reed Evaluation of competitive differentiation of novel therapies and the impact of patient variability on efficacy in a psoriasis QSP platform Wednesday 15:10-16:40 |
II-87 Javier Reig-López Validation of a Semi-mechanistic model with first-pass metabolism, two metabolic pathways and intestinal efflux transporter implemented in PhysPK biosimulation software. Wednesday 15:10-16:40 |
II-88 Isabel Reinecke Levonorgestrel-Containing Contraceptives: Comparison of Daily Doses and Exposure for Various Routes of Administration by an Integrated Population Pharmacokinetic Analysis Wednesday 15:10-16:40 |
II-89 Dinko Rekic Higher Febuxostat Exposure observed in Japanese Compared to Caucasian Subjects Independent of Bodyweight Wednesday 15:10-16:40 |